# Phase 2 Myelodysplastic Syndromes trials: 87 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 87 trials in phase 2 for Myelodysplastic Syndromes that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 2 Myelodysplastic Syndromes trials: 87 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-2/myelodysplastic-syndromes

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 87
- Recruiting or not yet: 87
- Read on: November 19, 2026

## Trials

The 25 newest of 87, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 27, 2026 | NCT07896928 | Study of Allogeneic Stem Cell Transplant in Myelodysplastic Syndrome Following Conditioning With Fludarabine and Total Body Irradiation 800... | Sponsor not shown (see the record) | Phase 2 | Not yet recruiting | MDS, Myelodysplastic Syndrome MDS, Myelodysplastic Syndrome (MDS), Myelodysplastic Syndrome | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07896928) |
| September 14, 2026 | NCT07819396 | Depletion of CD45RA Positive Naive T Cells for the Prevention of Graft Versus Host Disease in Older Patients Undergoing Allogeneic... | Fred Hutchinson Cancer Center | Phase 2 | Not yet recruiting | Acute Biphenotypic Leukemia, Acute Leukemia, Acute Leukemia of Ambiguous Lineage, Acute Lymphoblastic Leukemia, Acute... | 52 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07819396) |
| July 31, 2026 | NCT07738510 | A Study to Evaluate Ofirnoflast in Adults With Very Low- to Intermediate-risk Myelodysplastic Syndromes Requiring Red Blood Cell... | Halia Therapeutics, Inc. | Phase 2 | Not yet recruiting | Myelodysplastic Syndromes, Anemia | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07738510) |
| July 13, 2026 | NCT07698080 | Dexamethasone, Intravenous Injection of Human Immunoglobulin, and Increased Infusion of Mononuclear Cells to Reduce Donor Specific... | Hematology department of the 920th hospital | Phase 2 | Not yet recruiting | Leukemia, Lymphoma, Thalassemia, Aplastic Anemia, Myelodysplastic Syndromes | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07698080) |
| June 30, 2026 | NCT07677306 | Age-Stratified Conditioning Regimen Efficacy for MDS Haplo-HSCT | Peking University People's Hospital | Phase 2 | Recruiting | Myelodysplastic Syndromes | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07677306) |
| June 9, 2026 | NCT07634536 | Automated Total Marrow and Lymphoid Irradiation for Allogeneic Hematopoietic Cell Transplant | Stanford University | Phase 2 | Not yet recruiting | Acute Myeloid Leukemia, Myeloproliferative Neoplasm, Myelodysplastic Syndromes | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07634536) |
| June 1, 2026 | NCT07616336 | Chidamide Monotherapy for Intermediate-to-High-Risk Myelodysplastic Syndromes | Zhongshan Hospital (Xiamen), Fudan University | Phase 2 | Not yet recruiting | Myelodysplastic Syndromes | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07616336) |
| May 12, 2026 | NCT07582172 | Total Marrow and Lymphoid Irradiation in Combination With Fludarabine and Melphalan as Conditioning for Allogeneic Peripheral Blood Stem... | City of Hope Medical Center | Phase 2 | Recruiting | Acute Myeloid Leukemia With Complex Karyotype, Myelodysplastic Chronic Myelomonocytic Leukemia, Myelodysplastic... | 35 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07582172) |
| May 12, 2026 | NCT07579429 | Research On Nicotinamide Riboside Supplement Support in MDS (ROSS Trial) | University of Colorado, Denver | Phase 2 | Recruiting | Clonal Cytopenia of Undetermined Significance, Myelodysplastic Syndrome | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07579429) |
| May 7, 2026 | NCT07572929 | A Pragmatic Clinical Trial to Prevent Relapse for Myeloid Malignancies With Measurable Disease Prior to Allogeneic Transplant | Medical College of Wisconsin | Phase 2 | Not yet recruiting | Myeloid Disorders, Myelodysplastic Syndromes, Myeloproliferative Neoplasm, Acute Myeloid Leukemia | 450 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07572929) |
| May 5, 2026 | NCT07566377 | Cord Blood Transplantation in Children and Young Adults With Blood Cancer | Memorial Sloan Kettering Cancer Center | Phase 2 | Recruiting | Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, Non-hodgkin Lymphoma, Hodgkin... | 71 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07566377) |
| April 14, 2026 | NCT07528417 | Evaluation of Antibiotic Prophylaxis in Myelodysplastic Syndromes and Acute Myeloid Leukemia (MYELO-CAN:ABX) | University of Manitoba | Phase 2 | Not yet recruiting | Myeldysplastic Syndrome (MDS), MYELOPROLIFERATIVE DISORDER (P Vera, CMML, ET), Acute Myeloid Leukemia | 75 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07528417) |
| April 8, 2026 | NCT07516847 | Dapagliflozin for Anemia in Lower-Risk Myelodysplastic Syndromes | Sponsor not shown (see the record) | Phase 2 | Not yet recruiting | Myelodysplastic Syndromes (MDS), Anemia | 37 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07516847) |
| March 25, 2026 | NCT07493538 | MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With... | Masonic Cancer Center, University of Minnesota | Phase 2 | Recruiting | AML, MDS, Acute Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndromes | 132 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07493538) |
| March 11, 2026 | NCT07463820 | A Trial Comparing Three Different Treatment Options for Adults With Low-Risk Myelodysplasia and Anemia (A MyeloMATCH Treatment Trial) | National Cancer Institute (NCI) | Phase 2 | Not yet recruiting | Myelodysplastic Syndrome | 270 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07463820) |
| March 4, 2026 | NCT07449286 | IFN-α in Relapse Prevention. | Peking University People's Hospital | Phase 2 | Not yet recruiting | Acute Myeloid Leukemia, Myelodysplastic Syndromes | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07449286) |
| January 6, 2026 | NCT07319845 | A Study of TAK-226 for Anemia in Japanese Patients With Lower-Risk Myelodysplastic Syndromes | Takeda | Phase 2 | Recruiting | Myelodysplastic Syndromes | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07319845) |
| December 16, 2025 | NCT07285044 | The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment... | Mayo Clinic | Phase 2 | Recruiting | Amyloidosis, Basal Cell Carcinoma, Biliary Tract Carcinoma, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma... | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07285044) |
| November 20, 2025 | NCT07238686 | Venetoclax-containing Therapy Combined With Microtransplant for Intermediate-risk and Higher MDS | Beijing 302 Hospital | Phase 2 | Recruiting | Myelodysplastic Syndromes | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07238686) |
| November 14, 2025 | NCT07228273 | Induction and Consolidation With Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acute Myeloid Leukemia | OHSU Knight Cancer Institute | Phase 2 | Recruiting | Acute Myeloid Leukemia, Myelodysplastic Syndrome | 102 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07228273) |
| October 14, 2025 | NCT07216443 | Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic... | Orca Biosystems, Inc. | Phase 2 | Recruiting | Leukemia, Myeloid, Acute, Myelodysplastic Syndromes, Mixed Phenotype Acute Leukemia | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07216443) |
| September 4, 2025 | NCT07153497 | Testing the Use of an IDH1 Inhibitor, Olutasidenib, in Acute Myeloid Leukemia Added to ASTX727 and Venetoclax; in High-Risk MDS Added to... | National Cancer Institute (NCI) | Phase 2 | Not yet recruiting | Acute Myeloid Leukemia, Myelodysplastic Syndrome | 132 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07153497) |
| August 1, 2025 | NCT07098936 | Momelotinib in VEXAS Syndrome | Groupe Francophone des Myelodysplasies | Phase 2 | Recruiting | VEXAS Syndome, Myelo Dysplastic Syndrome | 57 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07098936) |
| July 1, 2025 | NCT07046078 | Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell... | Fred Hutchinson Cancer Center | Phase 2 | Recruiting | Acute Leukemia of Ambiguous Lineage, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07046078) |
| May 22, 2025 | NCT06984536 | Reduced ATG Plus Mini PTCy for GVHD Prophylaxis in Haplo-SCT | Peking University People's Hospital | Phase 2 | Recruiting | Myelodysplastic Syndrome, Acute Leukemia | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06984536) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| M.D. Anderson Cancer Center | 9 |
| National Cancer Institute (NCI) | 5 |
| Fred Hutchinson Cancer Center | 5 |
| Peking University People's Hospital | 4 |
| City of Hope Medical Center | 4 |
| Masonic Cancer Center, University of Minnesota | 3 |
| Fundación Pública Andaluza para la gestión de la Investigación en Sevilla | 2 |
| Beijing 302 Hospital | 2 |
| Mayo Clinic | 2 |
| University of Alabama at Birmingham | 2 |
| University of Manitoba | 2 |
| St. Petersburg State Pavlov Medical University | 2 |
| [Takeda](https://specstream.ai/data/clinical-trials/company/takeda) | 2 |
| Institute of Hematology & Blood Diseases Hospital, China | 2 |
| BioLite, Inc. | 1 |
| Memorial Sloan Kettering Cancer Center | 1 |
| Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 1 |
| Vastra Gotaland Region | 1 |
| Groupe Francophone des Myelodysplasies | 1 |
| Case Comprehensive Cancer Center | 1 |
| Washington University School of Medicine | 1 |
| [GlaxoSmithKline](https://specstream.ai/data/clinical-trials/company/glaxosmithkline) | 1 |
| University of Birmingham | 1 |
| Assistance Publique - Hôpitaux de Paris | 1 |
| Karolinska University Hospital | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 51 |
| China | 11 |
| Canada | 5 |
| France | 5 |
| Spain | 4 |
| Germany | 4 |
| United Kingdom | 4 |
| Sweden | 3 |
| Italy | 3 |
| Puerto Rico | 2 |
| Russia | 2 |
| Denmark | 2 |
| Japan | 2 |
| Poland | 1 |
| South Korea | 1 |
| Australia | 1 |
| Czechia | 1 |
| Israel | 1 |
| New Zealand | 1 |
| Belgium | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Business schools in the United States](https://specstream.ai/data/businesses/business-schools/united-states)
- [Tenant and eviction law firms in the United States](https://specstream.ai/data/businesses/tenant-and-eviction-law-firms/united-states)
- [Mongolian restaurants in the United States](https://specstream.ai/data/businesses/mongolian-restaurants/united-states)
- [Equipment rental companies in the United States](https://specstream.ai/data/businesses/equipment-rental-companies/united-states)
- [B2B domestic trade companies in the United States](https://specstream.ai/data/businesses/b2b-domestic-trade-companies/united-states)
- [Rheumatology practices in the United States](https://specstream.ai/data/businesses/rheumatology-practices/united-states)
